{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:37:01Z","timestamp":1794839821468,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The therapeutic landscape of castration-resistant prostate cancer (CRPC) has rapidly expanded. There is a need to develop noninvasive biomarkers to guide treatment. We established a highly sensitive method for analyzing androgen receptor gene (\n                    <jats:italic>AR<\/jats:italic>\n                    ) copy numbers (CN) and mutations in plasma circulating cell-free DNA (cfDNA) and evaluated the\n                    <jats:italic>AR<\/jats:italic>\n                    statuses of patients with CRPC.\n                    <jats:italic>AR<\/jats:italic>\n                    amplification was detectable in VCaP cell line (\n                    <jats:italic>AR<\/jats:italic>\n                    amplified) genomic DNA (gDNA) diluted to 1.0% by digital PCR (dPCR).\n                    <jats:italic>AR<\/jats:italic>\n                    mutation were detectable in LNCaP cell line (\n                    <jats:italic>AR<\/jats:italic>\n                    T878A mutated) gDNA diluted to 0.1% and 1.0% by dPCR and target sequencing, respectively. Next, we analyzed\n                    <jats:italic>AR<\/jats:italic>\n                    status in cfDNA from 102 patients.\n                    <jats:italic>AR<\/jats:italic>\n                    amplification and mutations were detected in 47 and 25 patients, respectively. As a biomarker,\n                    <jats:italic>AR<\/jats:italic>\n                    aberrations in pretreatment cfDNA were associated with poor response to abiraterone, but not enzalutamide. In serial cfDNA analysis from 41 patients, most\n                    <jats:italic>AR<\/jats:italic>\n                    aberrations at baseline diminished with effective treatments, whereas in some patients with disease progression,\n                    <jats:italic>AR<\/jats:italic>\n                    amplification or mutations emerged. The analysis of\n                    <jats:italic>AR<\/jats:italic>\n                    in cfDNA is feasible and informative procedure for treating patients with CRPC. cfDNA may become a useful biomarker for precision medicine in CRPC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-40719-y","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T07:02:58Z","timestamp":1552287778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Takayuki","family":"Sumiyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinari","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Okasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"40719_CR1","doi-asserted-by":"publisher","first-page":"15615","DOI":"10.3390\/ijms140815615","volume":"14","author":"T Kobayashi","year":"2013","unstructured":"Kobayashi, T., Inoue, T., Kamba, T. & Ogawa, O. Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci 14, 15615\u201315635, https:\/\/doi.org\/10.3390\/ijms140815615 (2013).","journal-title":"Int J Mol Sci"},{"key":"40719_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15, 701\u2013711, https:\/\/doi.org\/10.1038\/nrc4016 (2015).","journal-title":"Nat Rev Cancer"},{"key":"40719_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371, 424\u2013433, https:\/\/doi.org\/10.1056\/NEJMoa1405095 (2014).","journal-title":"N Engl J Med"},{"key":"40719_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368, 138\u2013148, https:\/\/doi.org\/10.1056\/NEJMoa1209096 (2013).","journal-title":"N Engl J Med"},{"key":"40719_CR5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","volume":"63","author":"H Beltran","year":"2013","unstructured":"Beltran, H. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63, 920\u2013926, https:\/\/doi.org\/10.1016\/j.eururo.2012.08.053 (2013).","journal-title":"Eur Urol"},{"key":"40719_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative Clinical Genomics of Advanced Prostate. Cancer. Cell 162, 454, https:\/\/doi.org\/10.1016\/j.cell.2015.06.053 (2015).","journal-title":"Cancer. Cell"},{"key":"40719_CR7","doi-asserted-by":"publisher","unstructured":"Wyatt, A. W. et al. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst 109, https:\/\/doi.org\/10.1093\/jnci\/djx118 (2017).","DOI":"10.1093\/jnci\/djx118"},{"key":"40719_CR8","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1158\/1078-0432.Ccr-14-2666","volume":"21","author":"AA Azad","year":"2015","unstructured":"Azad, A. A. et al. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res 21, 2315\u20132324, https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2666 (2015).","journal-title":"Clin Cancer Res"},{"key":"40719_CR9","doi-asserted-by":"publisher","first-page":"312re310","DOI":"10.1126\/scitranslmed.aac9511","volume":"7","author":"A Romanel","year":"2015","unstructured":"Romanel, A. et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 7, 312re310, https:\/\/doi.org\/10.1126\/scitranslmed.aac9511 (2015).","journal-title":"Sci Transl Med"},{"key":"40719_CR10","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/bjc.2015.128","volume":"112","author":"S Salvi","year":"2015","unstructured":"Salvi, S. et al. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer 112, 1717\u20131724, https:\/\/doi.org\/10.1038\/bjc.2015.128 (2015).","journal-title":"Br J Cancer"},{"key":"40719_CR11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","volume":"2","author":"AW Wyatt","year":"2016","unstructured":"Wyatt, A. W. et al. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA. Oncol 2, 1598\u20131606, https:\/\/doi.org\/10.1001\/jamaoncol.2016.0494 (2016).","journal-title":"Oncol"},{"key":"40719_CR12","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","volume":"28","author":"V Conteduca","year":"2017","unstructured":"Conteduca, V. et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol 28, 1508\u20131516, https:\/\/doi.org\/10.1093\/annonc\/mdx155 (2017).","journal-title":"Ann Oncol"},{"key":"40719_CR13","doi-asserted-by":"publisher","unstructured":"Annala, M. et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov, https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0937 (2018).","DOI":"10.1158\/2159-8290.Cd-17-0937"},{"key":"40719_CR14","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/2159-8290.Cd-13-0226","volume":"3","author":"JD Joseph","year":"2013","unstructured":"Joseph, J. D. et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 3, 1020\u20131029, https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-0226 (2013).","journal-title":"Cancer Discov"},{"key":"40719_CR15","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/2159-8290.Cd-13-0142","volume":"3","author":"M Korpal","year":"2013","unstructured":"Korpal, M. et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3, 1030\u20131043, https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-0142 (2013).","journal-title":"Cancer Discov"},{"key":"40719_CR16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/jco.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26, 1148\u20131159, https:\/\/doi.org\/10.1200\/jco.2007.12.4487 (2008).","journal-title":"J Clin Oncol"},{"key":"40719_CR17","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1158\/1078-0432.Ccr-12-3768","volume":"19","author":"H Gevensleben","year":"2013","unstructured":"Gevensleben, H. et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 19, 3276\u20133284, https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-3768 (2013).","journal-title":"Clin Cancer Res"},{"key":"40719_CR18","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1158\/0008-5472.Can-08-3605","volume":"69","author":"MP Steinkamp","year":"2009","unstructured":"Steinkamp, M. P. et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 69, 4434\u20134442, https:\/\/doi.org\/10.1158\/0008-5472.Can-08-3605 (2009).","journal-title":"Cancer Res"},{"key":"40719_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0864-1","volume":"17","author":"N Lallous","year":"2016","unstructured":"Lallous, N. et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol 17, 10, https:\/\/doi.org\/10.1186\/s13059-015-0864-1 (2016).","journal-title":"Genome Biol"},{"key":"40719_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10, 33\u201339, https:\/\/doi.org\/10.1038\/nm972 (2004).","journal-title":"Nat Med"},{"key":"40719_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787\u2013790, https:\/\/doi.org\/10.1126\/science.1168175 (2009).","journal-title":"Science"},{"key":"40719_CR22","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1158\/0008-5472.can-05-4000","volume":"66","author":"M Stanbrough","year":"2006","unstructured":"Stanbrough, M. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66, 2815\u20132825, https:\/\/doi.org\/10.1158\/0008-5472.can-05-4000 (2006).","journal-title":"Cancer Res"},{"key":"40719_CR23","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/annonc\/mdv267","volume":"26","author":"K Chi","year":"2015","unstructured":"Chi, K. et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 26, 2044\u20132056, https:\/\/doi.org\/10.1093\/annonc\/mdv267 (2015).","journal-title":"Ann Oncol"},{"key":"40719_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/iju.13346","volume":"24","author":"N Terada","year":"2017","unstructured":"Terada, N. et al. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. Int J Urol 24, 441\u2013448, https:\/\/doi.org\/10.1111\/iju.13346 (2017).","journal-title":"Int J Urol"},{"key":"40719_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371, 1028\u20131038, https:\/\/doi.org\/10.1056\/NEJMoa1315815 (2014).","journal-title":"N Engl J Med"},{"key":"40719_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13668","volume":"7","author":"C Henzler","year":"2016","unstructured":"Henzler, C. et al. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun 7, 13668, https:\/\/doi.org\/10.1038\/ncomms13668 (2016).","journal-title":"Nat Commun"},{"key":"40719_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep26483","volume":"6","author":"A Fujimoto","year":"2016","unstructured":"Fujimoto, A. et al. Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. Sci Rep 6, 26483, https:\/\/doi.org\/10.1038\/srep26483 (2016).","journal-title":"Sci Rep"},{"key":"40719_CR28","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/ng.3586","volume":"48","author":"B Niu","year":"2016","unstructured":"Niu, B. et al. Protein-structure-guided discovery of functional mutations across 19 cancer types. Nat Genet 48, 827\u2013837, https:\/\/doi.org\/10.1038\/ng.3586 (2016).","journal-title":"Nat Genet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40719-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40719-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40719-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T02:25:48Z","timestamp":1671243948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40719-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["40719"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-40719-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"9 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Osamu Ogawa and Tahahiro Inoue receive research grants from Astellas Pharma Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4030"}}